NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,https://clinicaltrials.gov/study/NCT00290498,,COMPLETED,"The overall goal of this clinical research study was to find out which of two different chemotherapy drug combinations, R-CHOP and R-HCVAD, is more effective in treating B-cell lymphoma.

At this point, all participants will now be assigned to the R-HCVAD arm of the study. Researchers will study the safety and effectiveness of this drug combination.",YES,Lymphoma,DRUG: Rituximab|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Dexamethasone|DRUG: Methotrexate|DRUG: Cytarabine|DRUG: Prednisone,"Response Rate R-HCVAD vs. R-CHOP, Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR., 3 years","Progression Free Survival (Rate), Progression free survival (PFS) for three years following therapy with Rituxan-HCVAD alternating with Rituximab with high -dose methotrexate/ara-C and standard R-CHOP in patients with newly diagnosed B-cell aggressive non-Hodgkin's lymphomas younger than 60 years old and with adjusted IPI 2 or higher adverse prognostic features., 3 years post-therapy",,M.D. Anderson Cancer Center,"Genentech, Inc.",ALL,"CHILD, ADULT",PHASE2,67,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-0054|NCI-2012-01355,2005-08-01,2017-08-11,2017-08-11,2006-02-13,2020-06-02,2020-06-02,"University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/98/NCT00290498/Prot_SAP_000.pdf"
